InflaRx is cutting approximately 30% of its employees in a bid to streamline its spending and pour more of its resources into its lead candidate. To accompany the layoffs, InflaRx will also pull money from its investigational antibody Gohibic, according to a press announcement Jan. 8.
All entries for: Discontinued Research
January 12, 2026
InflaRx
Discontinued Research, Layoffs
Jena, Germany
51-200 employees
Disease Area: Chronic Disease, Immune Diseases, Infectious Diseases
Drug Type: Biologic, Small Molecule
November 19, 2025
AbbVieÂ
Discontinued Research
North Chicago, IL
50,001+ employees
AbbVie has decided to call it quits with Google’s Calico Life Sciences. The move will involve layoffs affecting around 100 chemists. AbbVie will use the saved money to fund its biologics and cell and RNA therapies.
Disease Area: Oncology
Drug Type: Biologic
October 22, 2025
Galapagos
Discontinued Research, Layoffs
Cambridge, MA
1,001-5,000 employees
Galapagos intends to shutter its cell therapy business, which would affect about 365 employees across Europe, the United States and China and include site closures in New Jersey and Pennsylvania.
Disease Area: Chronic Disease, Immune Diseases, Multiple
Drug Type: Biologic, Small Molecule
June 25, 2025
Discontinued Research, Layoffs
Roughly a month after sharing that it would cut about half of its workforce, Leap Therapeutics has announced it will axe 75% of its staff over the next two months. The Cambridge, Massachusetts–based biotech is also winding down research and development activities and exploring strategic options that could include a sale, according to a June 23 SEC filing. The latest cuts affect 75% of the workforce, according to the filing, and will be carried out over two phases: one on or about June 30 and the second on or about July 31. The first round will include the departure of Augustine Lawlor, chief operating officer, while the second will include the exit of Cyndi Sirard, chief medical officer. Based on Leap having 52 full-time employees as of Dec. 31, according to its annual report, and the cuts detailed in a May 13 SEC filing, the company could have fewer than 10 staffers once the layoffs are complete.
Disease Area: Immune Diseases, Multiple, Oncology
Drug Type: Biologic
June 20, 2025
BioNTech
Discontinued Research, Layoffs
Gaithersburg, MD
5,001-10,000 employees
In conjunction with its decision to discontinue a study for one of its CAR T candidates, BioNTech will close down a cell therapy facility in Gaithersburg, Maryland, and lay off 63 employees at the site, according to a June 13 WARN notice and reporting from Fierce Pharma on Thursday.
Disease Area: Immune Diseases
Drug Type: Biologic, Small Molecule
May 20, 2025
Prime Medicine
Discontinued Research, Layoffs
Cambridge, MA
201-500 employees
As part of a strategic restructuring that includes deprioritizing its chronic granulomatous disease (CGD) programs, Prime Medicine is cutting about 25% of its staff and saying goodbye to its CEO, who resigned, the company announced May 19. The Cambridge, Massachusetts–based biotech had 214 full-time employees as of Dec. 31, 2024, according to an SEC filing, meaning the layoffs could affect about 54 people.
Disease Area: Hematology, Immune Diseases, Metabolic Diseases, Multiple, Respiratory Diseases
Drug Type: Biologic
February 13, 2025
Kojin Therapeutics
Discontinued Research
Boston, MA
1-50 employees
“Kojin Therapeutics will be restructuring and winding down its operations in the coming months. Since last year, with a new leadership team in place, we have made striking progress in developing first-in-class, small-molecule, ferroptosis inducers for potential use in patients with cancer and autoimmune diseases. However, obtaining sufficient funding to propel these programs forward into IND-enabling studies and clinical trials has proven difficult to achieve.”
1 Discontinued Research Program
Disease Area: Chronic Disease, Immune Diseases, Multiple, Oncology
Drug Type: Small Molecule
February 5, 2025
Takeda - Cambridge
Discontinued Research
Cambridge, MA
50,001+ employees
The clinical trial titled “A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)” (NCT06768658), sponsored by Takeda, was terminated due to business reasons before enrolling any participants. Specific details regarding these business reasons were not disclosed.
1 Discontinued Research Program
Disease Area: Chronic Disease
Drug Type: Small Molecule
January 20, 2025
Daiichi Sankyo
Discontinued Research
Basking Ridge, NJ
10,001-50,000 employees
A study on the efficacy of DS-2325a for patients with Netherton Syndrome was terminated based on a business decision by the sponsor.
1 Discontinued Research Program
Disease Area: Rare Diseases
Drug Type: Biologic
January 15, 2025
University of Rochester Medical Center
Discontinued Research
Rochester, NY
1-50 employees
The APATIT-G study was a pilot clinical trial conducted by the University of Rochester to evaluate the safety and effectiveness of avatrombopag in treating thrombocytopenia caused by temozolomide in glioma patients. However, the study was terminated by the sponsor before it could be completed.
1 Discontinued Research Program
Disease Area: Oncology
Drug Type: Small Molecule